Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings results on Thursday. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.09, MarketWatch Earnings reports. The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.21 million.

NASDAQ KPTI traded up $0.05 during trading hours on Friday, hitting $11.60. The company’s stock had a trading volume of 786,589 shares, compared to its average volume of 933,786. Karyopharm Therapeutics has a 12 month low of $9.00 and a 12 month high of $21.71. The company has a market capitalization of $721.92 million, a price-to-earnings ratio of -4.13 and a beta of 3.93.

KPTI has been the subject of several analyst reports. BidaskClub downgraded Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Wednesday, July 25th. Canaccord Genuity restated a “buy” rating and set a $27.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, August 7th. Robert W. Baird restated a “buy” rating and set a $25.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 8th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 29th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $22.90.

In related news, insider Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $11.65, for a total value of $145,625.00. Following the completion of the sale, the insider now directly owns 726,010 shares in the company, valued at approximately $8,458,016.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ltd Chione sold 251,468 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $20.94, for a total value of $5,265,739.92. The disclosure for this sale can be found here. Insiders sold a total of 735,788 shares of company stock valued at $14,720,105 over the last quarter. 13.26% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its holdings in Karyopharm Therapeutics by 5.1% in the 3rd quarter. BlackRock Inc. now owns 4,260,531 shares of the company’s stock worth $72,556,000 after buying an additional 204,897 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Karyopharm Therapeutics by 2.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 218,594 shares of the company’s stock valued at $3,723,000 after purchasing an additional 4,576 shares during the period. Candriam Luxembourg S.C.A. grew its stake in shares of Karyopharm Therapeutics by 120.6% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,085,500 shares of the company’s stock valued at $18,486,000 after purchasing an additional 593,500 shares during the period. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Karyopharm Therapeutics by 20.9% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,090 shares of the company’s stock valued at $683,000 after purchasing an additional 6,920 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Karyopharm Therapeutics by 14.1% during the 3rd quarter. Wells Fargo & Company MN now owns 42,274 shares of the company’s stock valued at $720,000 after purchasing an additional 5,239 shares during the period. Institutional investors own 71.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Karyopharm Therapeutics (KPTI) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/karyopharm-therapeutics-kpti-releases-quarterly-earnings-results-beats-estimates-by-0-09-eps/2598881.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Further Reading: Stock Symbols Definition, Examples, Lookup

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.